Viking Therapeutics Inc (VKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.73B
Last updated: Nov 17, 2026 at 11:05 AM ET
Viking Therapeutics Inc (VKTX) Earnings: Report Dates and Results
Viking Therapeutics (VKTX) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Viking Therapeutics reported EPS of -$1.55, below the -$1.06 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VKTX has an expected report date of Feb 9, 2027.
VKTX Earnings Call
The latest VKTX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, VKTX beat 17, missed 19 and matched 4. The widest gap in the table came in the quarter ended Dec 31, 2025, when EPS landed 53.33% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.55 | -$1.06 | -$1.38 - -$0.66 | -46.23% | Miss | N/A | 17 | 9 up, 6 down | Oct 28, 2026 |
| Jun 30, 2026 | -$1.10 | -$1.21 | -$1.39 - -$0.83 | +9.09% | Beat | N/A | 16 | 3 up, 8 down | Jul 29, 2026 |
| Mar 31, 2026 | -$1.37 | -$0.91 | -$1.43 - -$0.58 | -50.55% | Miss | N/A | 12 | N/A | Apr 29, 2026 |
| Dec 31, 2025 | -$1.38 | -$0.90 | -$1.06 - -$0.79 | -53.33% | Miss | N/A | 14 | 0 up, 1 down | Feb 11, 2026 |
| Sep 30, 2025 | -$0.81 | -$0.67 | -$0.80 - -$0.44 | -20.90% | Miss | N/A | 12 | 0 up, 0 down | Oct 22, 2025 |
| Jun 30, 2025 | -$0.58 | -$0.44 | -$0.55 - -$0.37 | -31.82% | Miss | N/A | 16 | 0 up, 10 down | Jul 23, 2025 |
| Mar 31, 2025 | -$0.41 | -$0.31 | -$0.42 - -$0.16 | -32.26% | Miss | N/A | 12 | 0 up, 3 down | Apr 23, 2025 |
| Dec 31, 2024 | -$0.32 | -$0.27 | -$0.34 - -$0.22 | -18.52% | Miss | N/A | 12 | 3 up, 3 down | Feb 5, 2025 |
| Sep 30, 2024 | -$0.22 | -$0.24 | -$0.32 - -$0.21 | +8.33% | Beat | N/A | 13 | 0 up, 0 down | Oct 23, 2024 |
| Jun 30, 2024 | -$0.20 | -$0.27 | -$0.32 - -$0.17 | +25.93% | Beat | N/A | 12 | 0 up, 0 down | Jul 24, 2024 |
| Mar 31, 2024 | -$0.26 | -$0.28 | -$0.32 - -$0.24 | +7.14% | Beat | N/A | 10 | 0 up, 0 down | Apr 24, 2024 |
| Dec 31, 2023 | -$0.25 | -$0.25 | -$0.28 - -$0.22 | 0.00% | In line | N/A | 9 | 1 up, 0 down | Feb 7, 2024 |
| Sep 30, 2023 | -$0.23 | -$0.22 | -$0.24 - -$0.18 | -4.55% | Miss | N/A | 11 | 1 up, 0 down | Oct 25, 2023 |
| Jun 30, 2023 | -$0.19 | -$0.20 | -$0.24 - -$0.15 | +5.00% | Beat | N/A | 11 | 0 up, 0 down | Jul 26, 2023 |
| Mar 31, 2023 | -$0.25 | -$0.24 | -$0.27 - -$0.21 | -4.17% | Miss | N/A | 10 | 0 up, 0 down | Apr 26, 2023 |
| Dec 31, 2022 | -$0.26 | -$0.23 | -$0.28 - -$0.21 | -13.04% | Miss | N/A | 10 | 0 up, 0 down | Feb 8, 2023 |
| Sep 30, 2022 | -$0.21 | -$0.23 | -$0.25 - -$0.20 | +8.70% | Beat | N/A | 10 | 1 up, 0 down | Oct 26, 2022 |
| Jun 30, 2022 | -$0.23 | -$0.21 | -$0.24 - -$0.18 | -9.52% | Miss | N/A | 10 | 1 up, 0 down | Jul 27, 2022 |
| Mar 31, 2022 | -$0.21 | -$0.19 | -$0.23 - -$0.18 | -10.53% | Miss | N/A | 9 | 0 up, 0 down | Apr 27, 2022 |
| Dec 31, 2021 | -$0.16 | -$0.19 | -$0.22 - -$0.17 | +15.79% | Beat | N/A | 9 | 0 up, 0 down | Feb 9, 2022 |
| Sep 30, 2021 | -$0.17 | -$0.21 | -$0.23 - -$0.20 | +19.05% | Beat | N/A | 10 | N/A | Nov 3, 2021 |
| Jun 30, 2021 | -$0.20 | -$0.20 | -$0.21 - -$0.19 | 0.00% | In line | N/A | 13 | N/A | Jul 28, 2021 |
| Mar 31, 2021 | -$0.19 | -$0.17 | -$0.20 - -$0.15 | -11.76% | Miss | N/A | 14 | N/A | Apr 28, 2021 |
| Dec 31, 2020 | -$0.15 | -$0.15 | -$0.18 - -$0.12 | 0.00% | In line | N/A | 15 | N/A | Feb 17, 2021 |
| Sep 30, 2020 | -$0.13 | -$0.15 | -$0.20 - -$0.13 | +13.33% | Beat | N/A | 15 | N/A | Oct 28, 2020 |
| Jun 30, 2020 | -$0.13 | -$0.14 | -$0.17 - -$0.12 | +7.14% | Beat | N/A | 15 | N/A | Jul 29, 2020 |
| Mar 31, 2020 | -$0.13 | -$0.12 | -$0.14 - -$0.10 | -8.33% | Miss | N/A | 11 | N/A | Apr 30, 2020 |
| Dec 31, 2019 | -$0.10 | -$0.13 | -$0.16 - -$0.09 | +23.08% | Beat | N/A | 12 | N/A | Feb 26, 2020 |
| Sep 30, 2019 | -$0.08 | -$0.12 | -$0.17 - -$0.11 | +33.33% | Beat | N/A | 12 | N/A | Nov 5, 2019 |
| Jun 30, 2019 | -$0.11 | -$0.09 | -$0.12 - -$0.07 | -22.22% | Miss | N/A | 11 | N/A | Aug 1, 2019 |
| Mar 31, 2019 | -$0.07 | -$0.09 | -$0.10 - -$0.06 | +22.22% | Beat | N/A | 9 | N/A | May 2, 2019 |
| Dec 31, 2018 | -$0.07 | -$0.10 | -$0.12 - -$0.09 | +30.00% | Beat | N/A | 10 | N/A | Mar 13, 2019 |
| Sep 30, 2018 | -$0.11 | -$0.11 | -$0.14 - -$0.10 | 0.00% | In line | N/A | 7 | N/A | Nov 7, 2018 |
| Jun 30, 2018 | -$0.13 | -$0.12 | -$0.14 - -$0.08 | -8.33% | Miss | N/A | 6 | N/A | Aug 9, 2018 |
| Mar 31, 2018 | -$0.08 | -$0.12 | -$0.17 - -$0.09 | +33.33% | Beat | N/A | 4 | N/A | May 9, 2018 |
| Dec 31, 2017 | -$0.14 | -$0.17 | -$0.20 - -$0.12 | +17.65% | Beat | N/A | 4 | N/A | Mar 7, 2018 |
| Sep 30, 2017 | -$0.22 | -$0.20 | N/A | -10.00% | Miss | N/A | N/A | N/A | Nov 8, 2017 |
| Jun 30, 2017 | -$0.21 | -$0.19 | N/A | -10.53% | Miss | N/A | N/A | N/A | Aug 9, 2017 |
| Mar 31, 2017 | -$0.23 | -$0.18 | N/A | -27.78% | Miss | N/A | N/A | N/A | May 10, 2017 |
| Dec 31, 2016 | -$0.18 | -$0.20 | N/A | +10.00% | Beat | N/A | N/A | N/A | Mar 21, 2017 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.18, after -$1.00 the year before. It was -$1.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.18 | N/A |
| Dec 31, 2024 | -$1.00 | N/A |
| Dec 31, 2023 | -$0.92 | N/A |
| Dec 31, 2022 | -$0.91 | N/A |
| Dec 31, 2021 | -$0.72 | N/A |
| Dec 31, 2020 | -$0.54 | N/A |
| Dec 31, 2019 | -$0.36 | N/A |
| Dec 31, 2018 | -$0.39 | N/A |
| Dec 31, 2017 | -$0.80 | N/A |
| Dec 31, 2016 | -$1.00 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 22 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,671 | 22 | |
| 2026Q2 | Jun 30, 2026 | 7,472 | 19 | |
| 2025Q4 | Dec 31, 2025 | 6,244 | 17 | |
| 2025Q3 | Sep 30, 2025 | 6,467 | 17 | |
| 2025Q2 | Jun 30, 2025 | 5,559 | 18 | |
| 2024Q4 | Dec 31, 2024 | 6,151 | 16 | |
| 2024Q3 | Sep 30, 2024 | 6,686 | 14 | |
| 2024Q2 | Jun 30, 2024 | 6,914 | 14 |
2026Q3 Earnings Call
Opening remarks
Stephanie Diaz Manager of Investor Relations Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; Greg Zante, Viking's CFO; and Hubert Chen, Viking's Chief Medical Officer. Before we begin, I'd like to caution that comments made during this conference call today, October 28, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lian for his initial comments.
Brian Lian President and CEO Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today, we'll review our financial results for the third quarter and 9 months ended September 30, 2026, and review recent updates across our pipeline programs and organization. During the third quarter, we made important progress across multiple pipeline programs and announced positive results from an innovative maintenance dosing study in our obesity program. With respect to our lead compound, VK2735, a dual agonist of the GLP-1 and GIP receptors, Viking's Phase III VANQUISH clinical program continued to proceed according to plan. The VANQUISH program is evaluating the subcutaneous formulation of VK2735 in two studies: VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes. Both trials are fully enrolled, and during the third quarter, both continued to advance toward completion. In addition, during the third quarter, the company made significant progress with its oral VK2735 program. Earlier this month, we announced the initiation of the SUNRISE Phase III registration program. As with the VANQUISH program for subcutaneous VK2735, the SUNRISE Phase III program consists of two studies, one evaluating the treatment of adults with obesity and the other evaluating adults with obesity and type 2 diabetes. We're very happy to have these important studies underway, and I'll provide more details on them in a few minutes. During the quarter, we also announced positive data from our novel VK2735 maintenance dosing study. Part 1 of this study was focused on our subcutaneous formulation and demonstrated an exciting signal that indicates the potential for novel dosing strategies to manage weight loss long term with lower and less frequent dosing regimens.
Frequently Asked Questions About VKTX
When is Viking Therapeutics's next earnings date?
Viking Therapeutics's next earnings report is expected for Feb 9, 2027.
Did VKTX beat earnings estimates last quarter?
No. Viking Therapeutics reported EPS of -$1.55 for the quarter ended Sep 30, 2026, below the -$1.06 estimate by 46.23%.
What EPS do analysts expect from VKTX next quarter?
The consensus EPS estimate for Viking Therapeutics for the quarter ending Dec 31, 2026 is -$1.32 from 22 analysts, with estimates from -$1.60 to -$0.79.
How often does VKTX beat earnings estimates?
Viking Therapeutics beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -30.56%.
VKTX pages: Overview, Earnings, Forecast, Financials, Competitors